3 October 2024 F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic.
UK biotech Arecor Therapeutics’ shares edged up more than 2% to 190.00 pence today, after it announced the signing of further collaboration agreement with US pharma major Eli Lilly. 29 November 2023
California, USA-based biotech firm BioMarin Pharmaceutical (Nasdaq: BMRN) has announced an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement amount for Roctavian (valoctocogene roxaparvovec-rvox) for people with severe hemophilia A. 29 November 2023
Tokyo-based Daiichi Sankyo (TYO: 4568) has announced that its booster vaccine Daichirona for Intramuscular Injection (DS-5670) has been approved as an Omicron XBB.1.5-adapted monovalent mRNA vaccine against COVID-19. 29 November 2023
Belgian biotech Agomab Therapeutics today announced the appointment of Dr Angelika Jahreis as an independent non-executive director to its board of directors, while Andrea Sáez will join Agomab’s executive leadership team as chief development officer. 29 November 2023
The US Food and Drug Administration (FDA) yesterday said it has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous chimeric antigen receptor (CAR)-T cell immunotherapies. 29 November 2023
Shares of Dutch immunology specialist Argenx (Euronext: ARGX) have dropped around a tenth following negative results from the ADVANCE-SC study. 29 November 2023
US biopharma Novavax has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for its updated COVID-19 jab for active immunization to prevent COVID-19 in people aged 12 and older. 28 November 2023
Shares of US RNA-focussed biotech Avidity Biosciences leapt as much as 35% pre-market, after it announced a global licensing and research collaboration with pharma major Bristol Myers Squibb focused on the discovery, development and commercialization of multiple cardiovascular targets. 28 November 2023
Canada’s Xenon Pharmaceuticals has reported top-line results from the Phase II X-NOVA trial, showing the primary efficacy endpoint was not met. 28 November 2023
The US Food and Drug Administration (FDA) has accepted and granted priority review for the Biologics License Application (BLA) for prademagene zamikeracel (pz-cel), submitted by Abeona Therapeutics. 28 November 2023
USA-based venture capital and private equity company focused on life sciences, Flagship Pioneering, has marked the official opening of its UK hub. 28 November 2023
Roivant Sciences’ shares fell 4.7% to $8.70 in early morning trading yesterday, after it announced the Phase II study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint. 28 November 2023
UK biotech start-up Myricx Bio has announced the publication today of ground-breaking research in Nature Cell Biology by its collaborators at the MRC-LMS (Laboratory of Medical Sciences) that has uncovered the central role of NMT as a druggable pathway in senescence. 28 November 2023
British pharma major AstraZeneca has established a new R&D center in Hong Kong, focused on research and development in areas including cell and gene therapies. 27 November 2023
Positive top-line data from the blinded extension phase of its Phase IIb ENLIVEN trial evaluating treatment with pegozafermin in patients with non-alcoholic steatohepatitis (NASH) were released today by 89bio. 27 November 2023
Following on from a deal announced last week, Swiss cancer company Oncoteq has unveiled an in-licensing agreement for an antibody-drug conjugate (ADC), codenamed TEQ102. 27 November 2023
Having pulled its multiple myeloma drug Blenrep (belantamab mafodotin) off the US market in 2022, and getting a negative recommendation from the European regulator in September this year, UK pharma major GSK has come back with promising new clinical data. 27 November 2023
The second Dupixent (dupilumab) investigational Phase III chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly reduced (34%) exacerbations. 27 November 2023
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.